Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness, Safety, and Tolerability of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals: 48-week Follow-up in Mexico

NCT06907056 is registered in ClinicalTrials.gov with José Antonio Mata Marín as lead sponsor.

NCT NCT06907056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness, Safety, and Tolerability of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals: 48-week Follow-up in Mexico
Lead sponsor
José Antonio Mata Marín
Phase
Phase 4
Overall status
Recruiting
Start date
November 9, 2023
Completion date
November 30, 2026
Enrollment
138 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection